Biotech News

Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease

Beam Therapeutics (BEAM)Beam TherapeuticsClinical readout

BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary Safety Endpoints at the Prespecified Interim Analysis Study Met All Secondary Endpoints Including

Related news

Beam Therapeutics

Base Editing Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities. BEAM-302 BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is...

Recent company news

Stock data

Close
20.94 USD
Market cap
2.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States